Fourteen articles were deemed relevant for this review. The primary purpose of the majority of these studies was to investigate the utility of the 6MWT for patients with CHF. Samples varied from 14 to 63 with 3 studies reporting sample sizes larger than 100 participants.11–13
Two of the studies, Cahalin14
used testers who were blinded to the results of the studies.
A common factor across many of the studies was the use of maximal exercise testing to acquire information regarding VO2
max. Seven of the studies used symptom-limited bicycle ergometry,10-16
because bicycle ergometry was less troublesome for the patient to perform, especially in the elderly population. Six studies used maximal symptom-limited treadmill testing.17–22
The shuttle-walk test was used in several studies as a comparison against the 6MWT,16,17,21
one of which showed high predictive value for VO2
Seven studies examined test-retest reliability; one of which showed good reliability and reproducibility.12–16,22,23
focused solely on reliability of the 6MWT, finding significant reliability in patients with no change in cardiac status upon follow-up (ICC=0.91), as well as in all patients across the entire sample (ICC > 0.75).
Two studies found that 6MWD ≤ 300 m was significantly able to predict likelihood of death or poorer outcomes in 6 months (p = .04)14
and worse prognostic outcomes (p = .013).12
Two other studies determined that distances ≤ 450m (r = 0.98, p = 0.33) and ≤ 490m (r = 0.76, p < 0.001), respectively also correlated with VO2
Peeters et al20
determined that the distance covered in a 6MWT correlated to distance walked on a treadmill (p < .001). Another 4 studies showed high, but not statistically significant correlations between VO2
max and the 6MWD.13,18,19,22
also determined that patients with high VO2
max had lower variations in 6MWD, conversely, patients with low VO2
max (< 14 ml/kg/min) had higher variability of 6MWD. Four of the studies included did not find a significant correlation between 6MWD and VO2
max from exercise testing.10,11,15,17
Synopsis of Each Study and Author Recommendations Cahalin14
In order to evaluate the utility of the 6MWT in assessing patients with CHF, 45 patients with symptomatic CHF underwent symptom limited cardiopulmonary exercise testing and the 6MWT. The 6MWT correlated moderately with peak VO2 (r = .64, p < 0.001) in patients with heart failure referred for heart transplantation. Distance ambulated less than 300 m was predictive of hospitalization or death in the next 6 months (p = 0.04). The 6MWT was inferior to peak VO2 and %VO2 for prediction of long-term survival; therefore, its use as a test of long-term survival is uncertain. The 6MWT may predict maximal bicycle exercise testing in patients with advanced CHF. From this study, equations were formulated that predict peak VO2 from the distance walked with 6MWT. Lastly, the 6MWT predicted peak VO2 and short-term event free survival of patients with advanced heart failure.
This study of 7 subjects examined the 10 m shuttle walk test (SWT) compared with the 6MWT and a maximal symptom-limited treadmill test in patients with CHF. Heart rate, rate of perceived exertion, and ambulatory VO2 were examined. Distance ambulated during the 6MWT was not significantly correlated to predict VO2 or functional capacity. The 6MWT provides an assessment of the patient's ability to perform submaximal activities of daily living but does not provide a consistent prediction of mortality in patients with CHF. Green and colleagues suggested that the SWT is a more predictive measure of peak VO2 than 6MWT. Peak HR, RPE were similar from the SWT and the treadmill peakVO2 test compared with VO2 during 6MWT which was lower, suggesting the SWT elicits a more comparable exercise response and thus is a more valid measure of functional capacity than the 6MWT in patients with CHF. The physiologic responses observed during the 6MWT were not graded as in the SWT and the peak VO2 test, suggesting the 6MWT does not elicit the same physiologic response and is not as predictive as previously thought in testing functional capacity.
In order to assess the potential value of the 6MWT as an objective measure of exercise capacity in patients with CHF, the test was administered 6 times over 12 weeks to 18 patients with CHF, who also underwent cycle ergometer testing and conventional functional testing. During the 6MWT, 9 patients received encouragement and 9 did not. Results of the 6MWT were consistent after the first 2 trials (p < .001). Encouragement influenced the scores (p < .02); therefore, the 6MWT should be standardized, eg, without encouragement. The low correlation of 6MWT scores with the cycle ergometer test (r=.42) suggest the 6MWT measures more functional activities as opposed to laboratory exercise capacity. The authors concluded that the 6MWT is reproducible but has low correlation with maximal exercise capacity for patients with CHF.
In order to clarify the usefulness of available measures of functional status and exercise capacity, 43 patients with lung disease and CHF were given 4 questionnaires, the 6MWT, and a bicycle exercise test. Correlations between the questionnaires and the 6MWT were r = .0473-.0590 but no correlation was found between the cycle testing and the questionnaires. Correlation between the 6MWT and bicycle test was moderate (r = .579). Reproducibility testing showed good results with the 6MWT. Correlation of the 6MWT with the questionnaires and with cycle ergometer indicates that the 6MWT is a good measure of how the patients feel, how they function when performing daily activities, and of their exercise capacity as measured in the laboratory. The 6MWT was considered superior to the questionnaires in that it is objective and reproducible. The 6MWT appears to measure the patient's ability to undertake physically demanding activities of daily living and may be a useful tool to measure cardiorespiratory response after intervention.
Exercise capacity of 26 patients with NYHA class II-III and 10 normal subjects with a mean age of 58 (range 36-68) yrs old was assessed by determining the oxygen consumption attained during a maximal exercise test and by measuring the distanced walked during the 6MWT. There were significant differences in maximal oxygen consumption between normal subjects, patients with class II heart failure and class III heart failure (p < 0.001). The distances walked in the third trial of the 6MWT were 683 meters in the normal subjects, 559 meters in class II patients, and 402 meters in class III patients. Maximal oxygen consumption was related in a curvilinear manner to the distance walked during the 6MWT. The findings of the study indicate that the 6MWT can objectively assess exercise capacity in patients with CHF. The patients preferred the 6MWT to the treadmill, finding it easier and more closely related to their daily physical activity. This finding may explain the wide range of distances covered in 6 minutes among those patients with low maximal oxygen consumption. Some may have been poor performers on the treadmill test and gave a better demonstration of their abilities during the 6MWT. The authors conclude that in patients with CHF the 6MWT provides an objective assessment of exercise capacity that could usefully supplement clinical information obtained from the history and physical examination.
The purpose of the study was to investigate whether the 6MWT distance was related to peak VO2 for individuals with advanced heart failure. A total of 307 subjects (mean age of 52 yrs, SD 13 yrs) and an ejection fraction less than 35% were studied. For patients with a peak VO2 of 10-20 mL/kg/min, the 6MWT was poorly correlated with peak VO2 (r = .28). For patients with higher (>20 mL/kg/min) or lower (<10 mL/kg/min) peak VO2, 6MWT moderately correlated with peak VO2 (r = .57). The 6MWT distance was not well correlated with peak VO2 and therefore considered not valid to predict peak VO2 for patients with advanced heart failure.
In this study, investigators assessed the 6MWT and the Shuttle Walk Test (SWT) with respect to peak VO2
, as measured by cycle ergometry, to determine the tests' utility as a measure of functional capacity in patients with CHF. Similar to Riley,22
the 6MWT had good reproducibility only after the first of 3 trials, with a significant difference in distance walked between trial 1 and 2 (p = 0.03), but not between trials 2 and 3 (r = 0.98, p = 0.33). The 6MWT was moderately correlated with peak VO2
levels (r = 0.69, p < 0.001). It was considered a significant predictor of peak VO2
< 14 mL/kg/min, with 83% accuracy (p = 0.02), with the best cut-off distance being 450 meters (sensitivity 80%, specificity 83%). For distances less than 450 meters, the 6MWT lost its significance as a peak VO2
predictor. Findings of a multivariate analysis indicated that only SWT distance (p < 0.001) and not 6MWT distance was considered to be an independent predictor of peak VO2
. The SWT was also only reproducible after a practice test, but overall, it was correlated more strongly with peak VO2
than the 6MWT.
The authors suggest that one reason for the stronger correlation and predictive value of the SWT was because both the cycle ergometry test and the SWT are symptom limited, unlike the 6MWT which is time limited. Analysis of the clinical data also suggested that the SWT was a better correlate to the exercise test in that the SWT was significantly more strenuous for the patients than the 6MWT [with respect to maximum heart rate, systolic blood pressure, and rate of perceived exertion (RPE)], but was not significantly different when compared to the cycle ergometry test (with respect to systolic blood pressure and RPE). They concluded that the 6MWT appears inferior to the SWT with respect to predicting functional capacity as defined as peak VO2, although still considered to have good reproducibility, moderate correlation with peak VO2 levels, and is 83% accurate in predicting peak VO2 (<14 mL/kg/min) as long as distance walked is greater than 450 meters.
Forty-one patients with CHF were assessed with commonly used function, health status, and quality of life measures, including maximal cardiopulmonary exercise testing, the Duke Activity Status Index (DASI), the Veterans Specific Activity Questionnaire (VSAQ), the Kansas City Cardiomyopathy Questionnaire (KCCQ), and the 6MWT. Peak VO2 demonstrated a significant but low relationship with the VSAQ score (r = 0.37) and no relationship with the DASI. Among the KCCQ domains, peak VO2 was significantly associated with quality of life score (r = 0.46) but not with physical limitations, symptoms, or clinical summary scores. The 6MWT distance was significantly though modestly related to peak VO2 (r = 0.49), KCCQ physical limitation (r = 0.53), and clinical summary scores (r = 0.44). The authors suggest that commonly used functional measures, estimates of quality of life, and symptom tools in patients with CHF have modest associations with peak VO2 and with one another. They further recommend that each test or instrument target a specific aspect of clinical status; they should not be considered interchangeable; and, that none of these measures alone is a reliable replacement for peak VO2.
While this longitudinal study did not examine peak VO2 levels as it relates to the 6MWT, it did investigate the reproducibility and responsiveness to change of the 6MWT, as well as the chronic heart failure questionnaire (CHQ), in more elderly patients (mean age 82 yrs, range 74-92) with heart failure. The 6MWT demonstrated excellent reproducibility (after re-testing 3 and 8 weeks later) with an intraclass correlation coefficient R =0.91. Data were only analyzed for the 24 of 45 patients who performed the second test. They reported no major overall change in cardiac status; those who reported that they had gotten better or worse were excluded from the second test. This global rating of change had good to moderate correlation with the dyspnea quality of life (QOL) (r = .70), fatigue QOL (r = .69), and total QOL scores (r = .77) as well as with walk distance (r = .78), but less moderate correlation to emotional QOL scores (r = .46) and heart failure score (CHQ) (r = -.56). Since questionnaires were involved in this study, the subjective nature of patient's answers could present bias. Despite possibly questionable assurance of lack of change with patient functional status between tests, the 6MWT demonstrated adequate reproducibility and responsiveness in elderly adults with CHF.
In this prospective trial, 37 patients were included on a 6MWT and a symptom-limited treadmill test. Participants with CHF NYHA classes II (16 patients) and III (10 patients) were compared with healthy, untrained controls (10 patients). Interestingly, all patients preferred the 6MWT to the treadmill test. This study had 8 participants (22%) drop out due to being unable to perform the treadmill test. The 6WMT distance was significantly different between NYHA classes II and III (p < .001), and control and NYHA class III (p < .001). No significant difference between control and NYHA class II. Significant lower symptomatic VO2 max occurred in NYHA class III than in NYHA class II (p = .032). The authors concluded that the 6MWT was correlated with treadmill distance, well tolerated by the elderly, and provided functional differentiation between NYHA classes II and III.
This study investigated the incremental shuttle walk test (ISWT) and the 6MWT with respect to test-retest reproducibility and accuracy in predicting peak VO2 in patients with stable CHF. The investigators used maximal incremental cardiopulmonary exercise testing to obtain peak VO2 levels. All 63 patients underwent cardiopulmonary exercise testing and then on a separate day were randomly assigned to 4 walk test groups (2 6MWT, 2 ISWT) with the repeated test performed 30 minutes later. Patients were verbally encouraged throughout the 6MWT each minute. With respect to test reproducibility, there was no significant difference in mean values for the 6MWT, with the mean bias close to 0 (1.96 SD). The 95% CI was 40 meters per Bland-Altman analysis. The 6MWT correlated well with peak VO2 levels (r = 0.76, p < 0.001), although there was wide variability in distance walked for the given peak VO2 level of 14 ml/kg/ min. The 6MWT was a significant predictor of significantly reduced peak VO2 (14 mL/kg/min or lower) with ROC curve = 0.91. The best predictive cut-off distance was 490 meters (sensitivity 83%, specificity 83%). A significant limitation with this study with respect to predicting functional capacity as measured by peak VO2 was that measurements were taken over a short span of time. The patients were also relatively young for people with CHF (51.3 yrs SD 10.2 yrs) and had a relatively “well-preserved” functional capacity, which may limit the predictive value of these tests. The results of the study suggest that the ISWT and the 6MWT have comparably modestly good reproducibility and accuracy in predicting significantly reduced peak VO2 in patients with stable CHF.
In this study investigators assessed the reproducibility of the 6MWT and its validity as a measure of functional capacity in patients with CHF. VO2 was measured not only during a treadmill exercise test, but also during performance of the 6MWT, providing for additional comparison. The 6MWT had good reproducibility after the first of 3 trials with a significant difference in distance walked between trial 1 and 2, but not 2 and 3; the 6MWT comparing trial 2 and 3 had a co-efficient of variance of 6.71. The 6MWT distance had good correlation with treadmill-measured peak VO2 (r = 0.88, p < 0.0001), as did the VO2 measured during the 6MWT (r = 0.90, p < 0.0001). Given that the VO2 measured during the 6MWT was less than the exercise treadmill test peak VO2 for all patients, it provides support for the notion that the 6MWT is a submaximal exercise test. Therefore the 6MWT provides for less variability in gait dynamics among subjects and a more accurate assessment of functional capacity. Patients may need to perform a practice trial of the 6MWT as reproducibility appears to only be accurate after the second test. The 6MWT has good correlation with peak VO2, but is likely a better measure of submaximal exercise.
The purpose of this study was to evaluate the potential of the 6MWT compared with peak VO2 in predicting outcome of patients with New York Heart Association (NYHA) class II or III heart failure. A total of 121 male and female subjects between the ages of 18-76 (mean age 59 yrs SD 11 yrs) with diagnosed heart failure for at least 3 months were included. Reliability was established for 40 of the 121 subjects by repeating the 6MWT twice in the same day (ICC = 0.82). This study has detection bias in that the 6MWT was not repeated in the whole study population. And although the intraclass correlation was high, it cannot be concluded that any improvement would not be observed, particularly in those patients walking shorter distances, which could modify to some extent the results reported. When using a threshold of 300 m the sensitivity of the 6MWT was 89%, specificity 60%, and positive predictive value 80%. There was a moderate correlation between distance walked and peak VO2 when a distance of 300 m was used as a threshold (r = 0.65).
The purpose of this study was to prospectively examine whether the distance ambulated during a 6MWT correlated with peak VO2. A total of 113 subjects with stable congestive heart failure (NYHA I-III) and ejection fraction less than 35% underwent symptom-limited bicycle cardiopulmonary exercise test while measuring peak VO2, and performed the 6MWT. Reliability was established by repeating the 6MWT for 10 subjects on 3 consecutive days (ICC = .96). There was a moderate correlation between distance ambulated and peak VO2 (r = .69 in men, r = .59 in women, p = 0.001). The 6MWT has predictive value of determining peak VO2 over time exhibited by moderate correlations between 6MWT and peak VO2 after 263 (SD 14) days (r = 0.71, p < 0.001) and after 381 (SD 170) days (r = 0.74, p < 0.001). The 6MWT correlated closely with peak oxygen uptake, has the ability to predict individual peak oxygen uptake, and can provide prognostic information of peak oxygen uptake.